S egmental osseous defects from traumatic injury or surgical intervention (eg, infections or tumors) are complicated problems with signifi cant long-term morbidity. Historically, due to the diffi culty in managing segmental long bone defects, amputation was the preferred treatment. Alternatives to amputation allowing limb salvage have been developed over the last half century. During World War II, massive cancellous bone autograft had been the principle alternative. 1, 2 The use of the Ilizarov technique, vascularized fi bular grafts, and acute limb shortening have been used previously to address defects of various lengths. Newer recombinant bone morphogenic proteins (BMPs) and calcium phosphate fi llers have also been used to treat this complex problem. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] More recently, the staged use of an antibiotic cement spacer followed by grafting within this space under the induced biomembrane formed around the spacer has been described as a potential treatment strategy. 22 This article describes a small series of patients at our institution successfully treated with this technique.
MATERIALS AND METHODS
We performed a retrospective review between 2007 and 2010 of all patients at a single institution who had sustained a long-bone segmental defect managed by initial placement of an antibiotic spacer block with staged bone grafting (Table) . The patients were evaluated for injury type, location, and mechanism; defect size; type of cement spacer; date of cement spacer placement; date of defi nitive treatment; type of defi nitive stabilization; material used to fi ll the void; date to union; date to full weight bearing; demographic data; and complications. Complications were considered nonunion, need for further surgery, infection, deep venous thrombosis (DVT), and/or pulmonary embolus. The review was carried out in accordance with the protocol approved by our Institutional Review Board.
SURGICAL TECHNIQUE
The segmental bone defect (Figure 1 ) is approached in a staged fashion with the second stage performed approximately 4 to 5 weeks from the placement of the spacer. During the fi rst stage, the operative extremity is prepped and draped in the usual sterile fashion. The area of bone loss is carefully debrided and irrigated, removing any gross debris and nonviable Once fi xation has been achieved, attention is then turned to the bone defect. The defect is measured and fi lled with a spacer made from polymethylmethacrylate (PMMA) bone cement (Simplex; Stryker, Mahwah, New Jersey). The amount of PMMA necessary to fi ll the void is based on the size of the defect. If concern exists for infection or the fracture is open, the cement may be mixed with vancomycin and/ or tobramycin. We prefer to use 2 g vancomycin and 2.4 g of tobramycin per 40 g of cement prepared. It is essential to fi ll the entire defect with the antibiotic spacer, from bone end to bone end ( Figure 2 ). Cement polymerization is an exothermic reaction that results in a slight amount of expansion in the initial volume of cement placed. For this reason, if too much cement is placed, it can be diffi cult to remove when the defect is later revisited for grafting. Therefore, we prefer to slightly undersize the cement block to allow for easier retrieval. The wound is then closed in a layered fashion with a watertight fascial closure, followed by skin closure using the Donati-Allgöwer technique. 23 This reduces the chance of wound drainage and/ or compromise to the soft tissue envelope.
At the second stage, performed 4 to 5 weeks later if soft tissue permits, the patient is positioned in an identical manner as the fi rst stage. If bone graft is to be harvested from the iliac crest, femoral canal, or other area, this should also be considered. The fracture is approached through the previous incision and careful dissection is performed down to the defect. If a plate and screw device was used, the pseudosynovial membrane will often form around the plate as well as the cement spacer. The plate, however, is palpable under the membrane. The biomembrane encapsulating the cement spacer is incised along the anterior border of the plate leaving enough tissue to reapproximate at the end of the case. Once exposed, the cement spacer is removed en bloc or in a piecemeal fashion. An osteotome can be used to longitudinally split the cement spacer into smaller pieces before removal. It is critical to be sure to remove all of the cement. It is tempting to lever on the plate to remove the spacer, but this should be avoided so as not to have unnecessary stress applied to the surgical construct. Once the cement spacer is removed, the biomembrane capsule is irrigated to remove any residual debris, being sure not to violate the membrane at any point.
With the defect open, bone graft and bone graft substitute is placed to fi ll the entire defect. A defect-fi lling osteoconductive material is necessary because these defects are often large enough that there is inadequate autograft available to fi ll the entire defect. In addition, osteoinductive and osteogenic agents can be used at the discretion of the surgeon. Our preference is to use crushed cancellous allograft, demineralized bone matrix (DBM 
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Grafton; Osteotech Inc, Eatontown, New Jersey), bone morphogenic protein-2 (BMP-2) (Infuse; Medtronic, Memphis, Tennessee), and local or iliac crest bone graft. Platelet-rich concentrate (Caption; Smith & Nephew, Memphis, Tennessee) was also included in certain instances. The defect should be completely fi lled, but not overstuffed. Overfi lling the defect will prevent closure of the biomembrane. Once the defect is fi lled, the biomembrane is closed with absorbable Vicryl suture (Ethicon, Inc, Somerville, New Jersey), followed by wound closure in a layered fashion. Again, it is important to obtain a watertight fascial closure, followed by skin closure using Donati-Allgöwer technique. 23 Patients are allowed immediate passive motion and weight bearing is determined by fracture location and stability. Weight bearing is increased starting approximately 6 weeks after the second stage based on radiographic healing and formation of new bone (Figure 3) .
RESULTS
A total of 11 consecutive patients were identifi ed within the time period. All patients were treated by the senior author (S.M.) and deemed at the time of presentation to require staged management of their osseous defects. Eight men and 3 women had an average age of 45.4 years (range, 15-84 years). Five femurs and 6 tibias were treated with this technique. There were 5 cases of acute traumatic bone loss, 3 cases of an infected nonunion, 2 cases of sterile nonunions, and 1 case of delayed infection following femoral reconstruction with structural allograft following tumor resection. Average defect size was 8.5 cm (range, 4-15 cm). Average time from spacer placement to defi nitive treatment was 58 days (range, 32-92 days).
Defi nitive stabilization included plating (8 patients), intramedullary nailing (2 patients), and revision from a plate construct to a fi ne-wire fi xator at the time of staged bone grafting (1 patient). Type of fi xation (plate or nail) was determined by location and morphology of the defect. In 2 cases, an antibiotic intramedullary nail was placed at the time of spacer placement because an infected intramedullary device had been removed. At the time of bone grafting, provisional fi xation of the limb was achieved with an external fi xator, the antibiotic nail and spacer were removed and an unreamed intramedullary device was then placed. The contralateral limb was used to determine overall length, alignment and rotation. Throughout the procedure, care was taken to avoid injury to the biomembrane.
The void left by the antibiotic spacer was fi lled with a combination of allograft, autograft (when available) BMP-2, demineralized bone matrix, and platelet-rich concentrate. The senior author made the determination of which biologics were used at the time of surgery. In almost all cases, cancellous allograft and demineralized bone matrix was used to provide the majority of the volume to the implanted graft. Bone morphogenic protein was also used in every case except for 2. In the fi rst case, the treating surgeon did not want to use BMP-2 at the time of grafting, and in the second, there was adequate autograft available following resection of heterotopic bone from the patient's ipsilateral hip as well as the predisposition of this specifi c patient to form heterotopic bone. In all cases, if an adequate quantity of autograft was not available, and the patient consented to the use of platelet rich concentrate, it was also used. A specifi c formula for which biologic substances are used at the time of grafting has not been standardized but is the focus of continued research.
Ten of the 11 patients (90%) demonstrated radiographic consolidation of the defect an average of 226 days after defi nitive fi xation. Ten of the 11 (90%) were full weight bearing an average 133 days after defi nitive fi xation. There was 1 nonunion (9%) and 1 infection (9%), both of which occurred in the same patient. Interestingly, this nonunion occurred in the only patient who had iliac crest bone graft alone added to the void at the time of secondary bone grafting. One patient required hardware removal (9%) and 2 (18%) developed heterotopic ossifi cation. No DVTs or pulmonary emboli were reported.
DISCUSSION
Treatment of large segmental bone defects can be challenging for orthopedic surgeons. Bone grafting of these defects is often delayed after primary fi xation to allow soft tissue healing, decrease the risk of infection, and prevent graft resorption during the early infl ammatory healing phase. 23 In traumatic wounds, antibiotic impregnated cement beads or spacers are often used for local antibiotic administra- 
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tion to the soft tissue bed or within an osseous defect. In addition, the advantages of inserting such a spacer include maintaining the void to allow for later placement of graft, providing structural support, offl oading the implant, and inducing the formation of a biomembrane, which can function to contain secondary grafting. Masquelet 22 and Masquelet et al 24 fi rst described this technique of formation of a pseudosynovial membrane around a cement spacer with later bone grafting of the defect, proposing that this membrane prevents graft resorption and improves vascularity and corticalization. It has been described that after the initial placement of the antibiotic impregnated spacer, 4 to 5 weeks is needed for development and maturation of a biologically active membrane suitable for grafting. The spacer also maintains the defect and inhibits fi brous in growth. 25 Recent literature has shown that this biomembrane can be 0.5 to 1 mm thick 26 and has been described as both hypervascular and impermeable. 27 Pelissier et al 27 studied the properties of this membrane in a rabbit model and found that it secreted several growth factors including BMP-2, vascular endothelial growth factor, and transforming growth factor ␤-1 (TGF-␤1). Their research revealed that levels of BMP-2 were highest at 4 weeks. 27 Finally, Viateau et al 28 studied this technique in a sheep model and found that the membrane alone was inadequate to heal a large defect, but when autologous bone graft was placed within the membrane, all of the defects studied went on to heal. The technique of inducing a biomembrane at the site of an osseous defect with staged grafting has been described in multiple case reports for defects of various sizes and in various locations throughout the skeletal system. Biau et al 29 described the management of a 16-cm defect in the femur of a 12-year-old child who had been diagnosed with Ewing's sarcoma and required resection of a large segment of his femur. The segmental defect was stabilized with an intramedullary nail, then maintained with an antibiotic spacer until later grafting and eventual healing. 29 As mentioned, the technique has been used to address bone loss in areas other than long bones. Huffman et al 30 reported use of the technique in a signifi cant area of bone loss in the midfoot of a patient who had sustained multiple gunshot injuries. They obtained medullary autograft with the reamer-irrigator-aspirator from the ipsilateral femur for placement within the defect area, which was then stabilized with a plate and screw construct. 30 The original description of this technique described stabilization of the bone with an external fi xator, but as noted, other means of fracture fi xation have been used with success. Apard et al 31 reported a series of 12 patients who presented with segmental defects in the tibia Ͼ6 cm, all of whom were initially fi xed with an intramedullary nail. They reported healing following the second-stage procedure in 11 of 12 patients at an average of 4 months. 31 Our series included patients who had fracture fi xation with both intramedullary implants and locked plate constructs. To our knowledge, no study has evaluated the optimal biomechanical environment for such a technique, rather each fracture is "bridged" according to the treating surgeon's assessment of the fracture. A potential effect of a construct that is too rigid may be stress shielding near the plate, reducing integration of the bone graft near the implant. This does not preclude bony union but may increase time to osseous consolidation and affect the radiographic appearance of the defect.
The technique as described by Masquelet and Begue 25 relies on the placement of morselized cancellous autograft harvested from the iliac crests within the biomembrane lined defect. If this amount is not suffi cient, demineralized allograft is added to the autograft in a ratio that does not exceed 1:3. 25 No studies have compared the use of different auto-or allograft compositions used with this technique. Biau et al 29 used both iliac crest corticocancellous autograft as well as a medial tibial cortical strut autograft to fi ll their large defect. Use of cancellous autograft from the femoral canal has also been described, and evidence exists to show that levels of many growth factors (fi broblast growth factor-␣, plateletderived growth factor, insulin-like growth factor 1, TGF-␤1, and BMP-2) in femoral cancellous bone are present in higher concentrations than they are in iliac crest and platelet preparations. 32 In our series, we used a nonstandardized grafting technique that was determined by the individual defect size, patient profi le, and senior author's discretion. We used combinations of iliac crest bone graft, reamed femoral cancellous autograft, free fi bula allograft, recombinant BMP, platelet-rich concentrate preparations, demineralized bone matrix allograft, and crushed cancellous allograft to fi ll the residual defects. Further research and clinical series will hopefully elucidate the grafting components necessary to optimize healing in these patients.
CONCLUSION
The technique of delayed bone grafting after initial placement of a cement spacer provides a reasonable alternative for the challenging problem of signifi cant bone loss in extremity reconstruction. This technique can be used in either an acute or delayed fashion with equally promising results. The bioactivity of the membrane created by fi lling large bony defects with cement leads to a favorable environment for bone formation and osseous consolidation of a large void. As this technique becomes more widely applied, the answer to which graft substances to place in the void may become clearer. Increasing clinical evidence will also help support the use of this technique in treating segmental bone loss.
